Navidea Biopharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2PH4J / ISIN: US63937X2027

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Navidea Biopharmaceuticals Inc Registered Shs

12.05.22		Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results (Businesswire)
05.05.22		Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update (Businesswire)
16.12.21		Pre-market Movers: CALT, SABS, IRNT, CTK, VALN… (RTTNews)
15.07.21		Navidea Biopharma : FDA Meeting On Rheumatoid Arthritis To Take Place On Sept 1 (RTTNews)
24.06.21		Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty (Businesswire)
19.05.21		Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections (Businesswire)
11.05.21		Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results (Businesswire)
05.05.21		Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition (Businesswire)
04.05.21		Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update (Businesswire)
15.04.21		Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium (Businesswire)
24.03.21		Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
17.03.21		Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
02.03.21		Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference (Businesswire)
02.03.21		Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor (Businesswire)
08.02.21		Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis (Businesswire)
07.01.21		Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021 (Businesswire)
28.12.20		Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter (Businesswire)
13.11.20		Pre-market Movers In Healthcare Sector: UROV, NAVB, BNGO, DFFN, KROS… (RTTNews)
13.11.20		AZN's Repurposed COVID-19 Drug Fails, NAVB On Watch, CVAC Rallies On Storage Advantage Of CVnCoV (RTTNews)
12.11.20		Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results (Businesswire)
12.11.20		Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis (Businesswire)
05.11.20		Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
22.10.20		Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable (Businesswire)
09.10.20		Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting (Businesswire)
28.09.20		Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange (Businesswire)
08.09.20		Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference (Businesswire)
02.09.20		Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation (Businesswire)
24.08.20		Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference (Businesswire)
13.08.20		Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results (Businesswire)
10.08.20		Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership (Businesswire)
10.08.20		Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma (Businesswire)
06.08.20		Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
22.05.20		Stock Alert: Navidea Biopharma Shares Up 75% In Late Trade (RTTNews)
21.05.20		Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis (Businesswire)
14.05.20		Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results (Businesswire)
11.05.20		Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® (Businesswire)
07.05.20		Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update (Businesswire)
22.04.20		Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic (Businesswire)
31.03.20		Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates (Businesswire)
20.03.20		Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek® (Businesswire)
11.03.20		Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
04.03.20		Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update (Businesswire)
14.02.20		Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards (Businesswire)
14.02.20		Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding (Businesswire)
30.12.19		Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York (Businesswire)
07.12.19		Navidea Biopharmaceuticals Announces $1.9 Million Private Placement (Businesswire)
05.12.19		Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event (Businesswire)
02.12.19		Navidea Biopharmaceuticals Wins Summary Judgment in Ohio (Businesswire)
14.11.19		Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference (Businesswire)
07.11.19		Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

NVIDIA-Aktie mit Abwärtstrend: Cramer rät NVIDIA-Beteiligung zusammenzustreichen

Diese Aktien empfehlen Experten zu kaufen

Ripple Kurs Prognose: XRP bei 2,20 US-Dollar, folgt der Ausbruch?

Megaübernahme im Anmarsch? Shell will wohl BP kaufen

BYD und Aramco schmieden historische Allianz

Peter Brandt nennt Kryptowährung Ethereum "wertlosen Müll"

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	05.05.2025 11:20
Kaufwert:	EUR
	Hinzufügen Speichern

Navidea Biopharmaceuticals Aktie

WKN DE: A2PH4J / ISIN: US63937X2027

Nachrichten zu Navidea Biopharmaceuticals Inc Registered Shs

Newssuche

Meistgelesene Nachrichten